
zzso zzso zzso and zzso are well established as zzso markers for treatment benefit, although zzso deficiencies can still affect their zzso zzso The shift towards earlier diagnosis poses a challenge in identifying those low-risk patients who may safely avoid zzso chemotherapy for early breast zzso zzso recent research has focused on developing zzso to zzso residual risk on zzso zzso zzso For widespread adoption into clinical practice, these must be validated in zzso clinical trials and provide additional information to current standards using zzso and cost-effective zzso Furthermore, evidence from zzso studies indicates that zzso or zzso zzso can be more zzso than at zzso In particular, zzso has recently emerged as an intermediate marker of long-term zzso The power of zzso to predict treatment benefit from zzso therapy has facilitated the design of studies where zzso is the primary zzso This has also led to investigations into the zzso power of zzso to determine benefit from signal zzso zzso and chemotherapy in several recent and ongoing zzso 

